QRG Capital Management Inc. Sells 3,989 Shares of Sanofi $SNY

QRG Capital Management Inc. decreased its stake in shares of Sanofi (NASDAQ:SNY) by 2.6% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 146,827 shares of the company’s stock after selling 3,989 shares during the period. QRG Capital Management Inc.’s holdings in Sanofi were worth $7,093,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Accent Capital Management LLC bought a new stake in shares of Sanofi during the first quarter valued at approximately $29,000. Eastern Bank lifted its holdings in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after buying an additional 300 shares in the last quarter. Ameritas Advisory Services LLC bought a new position in Sanofi in the 2nd quarter valued at $28,000. Golden State Wealth Management LLC increased its stake in shares of Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after buying an additional 545 shares during the period. Finally, Banque Transatlantique SA bought a new stake in shares of Sanofi during the first quarter worth $33,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Trading Up 1.5%

SNY opened at $50.90 on Monday. The firm’s fifty day moving average is $48.19 and its two-hundred day moving average is $49.98. The firm has a market cap of $124.99 billion, a PE ratio of 12.24, a price-to-earnings-growth ratio of 1.24 and a beta of 0.51. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. Sanofi’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.73 EPS. Equities research analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on SNY. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Barclays restated an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research note on Saturday, September 27th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.